person
Gunnar C.
- Country
- Germany
- Department
- Klinik für Kinderonkologie und -rheumatologie
Research Overview
assignment
14
Clinical Trials ·
- Interfant-21: International collaborative treatment protocol for infants under one year with KMT2A-rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
- Reduced‑intensity post‑induction chemotherapy plus blinatumomab versus standard post‑induction therapy in pediatric standard‑risk B‑ALL (AIEOP‑BFM ALL 2025)
- Phase 3 Study of Imatinib with Cytotoxic Chemotherapy in Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
location_city
1
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
242
Sites with multiple studies
Has run more than one trial at 242 of 358 partner sites.
Specializations
Pediatric Leukemia
The investigator specializes in treating acute lymphoblastic leukemia (ALL) in children and adolescents, with particular emphasis on high-risk cases and innovative therapeutic approaches.
- B-cell precursor ALL treatment
- Philadelphia chromosome-positive ALL management
- Infant ALL therapy
- Relapsed/refractory disease interventions
Lymphoma Studies
Focus areas include the treatment of mature aggressive B-cell lymphoma and lymphoblastic lymphoma in pediatric populations.
- B-cell lymphoma protocols
- Rituximab-based therapies
- CNS disease management
- Risk-adapted treatment strategies
Sarcoma Treatment
Expertise in treating rhabdomyosarcoma through comprehensive therapeutic approaches incorporating various treatment modalities.
- Frontline therapy optimization
- Radiotherapy timing and dosing
- Maintenance therapy protocols
- Relapse management strategies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.